FDA Approves Gene Therapy for Tough-to-Treat Bladder Cancer
MONDAY, Dec. 19, 2022 (HealthDay News) — Patients with a high-risk bladder cancer now have a new option to treat it. The U.S. Food and Drug Administration on Friday approved a gene therapy called Adstiladrin, which is designed to work for patients who have what’s called high-risk non-muscle-invasive bladder cancerContinue Reading